Objective Serotonergic psychedelics are re-emerging as potential novel treatments for
several psychiatric disorders including major depressive disorder. The Canadian Network …

Introduction: Mood, anxiety, and substance-use disorders are among the most prevalent
psychiatric disorders in the population. Although several pharmacological treatments are …

MATERIALS AND METHODS We present a narrative review of the published literature
conducted by identifying contemporary clinical trials of serotonergic psychedelics for the …

Objective To conduct a systematic review of modern‐era (post‐millennium) clinical studies
assessing the therapeutic effects of serotonergic psychedelics drugs for mental health …

Rationale Major depressive disorder is one of the leading global causes of disability, for
which the classic serotonergic psychedelics have recently reemerged as a potential …

Background Psychedelic therapy shows promise for Major Depressive Disorder, especially
when treatment-resistant, as well as life-threatening illness distress. The objective of this …

Background Psilocybin is a serotonin receptor agonist that occurs naturally in some
mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for …

Background Psilocybin may have antidepressant properties, but direct comparisons
between psilocybin and established treatments for depression are lacking. Methods In a …

Background Depression and anxiety are prevalent psychiatric disorders that carry significant
morbidity. Pharmacological and psychosocial interventions are used to manage these …

Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD).
Objective To evaluate the magnitude, timing, and durability of antidepressant effects and …